Scarica l'app Stockscreener
7.885
0.06%
0.005
Precedente Chiudi:
$7.88
Aprire:
$7.89
Volume 24 ore:
1.76M
Relative Volume:
1.89
Capitalizzazione di mercato:
$370.11M
Reddito:
-
Utile/perdita netta:
$-82.60M
Rapporto P/E:
-3.8277
EPS:
-2.06
Flusso di cassa netto:
$-48.61M
1 W Prestazione:
-0.57%
1M Prestazione:
+225.83%
6M Prestazione:
+247.36%
1 anno Prestazione:
+71.41%
Intervallo 1D:
$7.85
$7.90
Intervallo di 1 settimana:
$7.85
$7.94
Portata 52W:
$1.312
$7.95
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Nome
Vigil Neuroscience Inc
Settore
Industria
Telefono
857-254-4445
Indirizzo
100 FORGE ROAD, WATERTOWN
Confronta VIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
7.885 | 370.11M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.45 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
503.30 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.71 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
583.64 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
108.02 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Downgrade | Stifel | Buy → Hold |
| 2024-12-04 | Iniziato | William Blair | Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2022-09-16 | Iniziato | Wedbush | Outperform |
| 2022-08-29 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Iniziato | Jefferies | Buy |
| 2022-02-01 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Iniziato | Stifel | Buy |
Mostra tutto
Vigil Neuroscience Inc Borsa (VIGL) Ultime notizie
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Vigil Neuroscience fails in mid-stage study for lead asset - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders - marketscreener.com
Vigil Neuroscience halts Phase 2 trial for ALSP treatment By Investing.com - Investing.com South Africa
Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease - insights.citeline.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasda - TradingView
Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes - TipRanks
Vigil Neuroscience (VIGL) Trial Results Impact Future Plans - GuruFocus
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - PR Newswire
Vigil Neuroscience halts Phase 2 trial for ALSP treatment - Investing.com Australia
Vigil Neuroscience stock slips on trial setback (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Trial | VIGL Stock News - GuruFocus
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - marketscreener.com
Clinical Setback: Vigil Neuroscience Halts Phase 2 ALSP Trial After Iluzanebart Shows No Efficacy - Stock Titan
Northern Trust Corp Has $110,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Tria - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? - sharewise
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The MergerPRA, AXL, SWTX and VIGL - The Malaysian Reserve
HC Wainwright Has Bearish Estimate for VIGL FY2026 Earnings - Defense World
Sanofi to acquire Vigil Neuroscience in $470-M deal - MSN
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold - Defense World
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - The Globe and Mail
Sanofi’s Acquisition Of Vigil Neuroscience - Global Legal Chronicle
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL St - GuruFocus
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL Stock News - GuruFocus
France: Sanofi adding to neurology pipeline with acquisition of Vigil Neuroscience - Investors in Healthcare
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by HC Wainwright to “Neutral” - Defense World
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 - Investing.com Australia
VIGL: HC Wainwright Downgrades Vigil Neuroscience, Lowers Price Target | VIGL Stock News - GuruFocus
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 By Investing.com - Investing.com India
Vigil Neuroscience (VIGL) Downgraded by Stifel Following Sanofi Deal | VIGL Stock News - GuruFocus
Vigil Neuroscience (VIGL) Downgraded Amid Acquisition Plans | VIGL Stock News - GuruFocus
Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments - TipRanks
HC Wainwright Downgrades Vigil Neuroscience to Neutral From Buy, Price Target is $8 - marketscreener.com
Wedbush Equities Analysts Reduce Earnings Estimates for VIGL - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Consensus Price Target from Brokerages - Defense World
Vigil Neuroscience Elects Directors at Annual Meeting - MSN
Vigil Neuroscience (NASDAQ:VIGL) Rating Lowered to “Hold” at Mizuho - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Cut to “Hold” at Guggenheim - Defense World
Vigil Neuroscience’s (VIGL) “Market Perform” Rating Reiterated at JMP Securities - Defense World
Sanofi to Acquire Vigil Neuroscience for Up to $600M in Alzheimer’s Drug Push - USA Herald
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Financial Post
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade - MSN
Vigil Neuroscience shareholders approve board nominees By Investing.com - Investing.com South Africa
Vigil Neuroscience Inc (VIGL) was downgraded to a Hold Rating at Mizuho Securities - The Globe and Mail
Vigil Neuroscience shareholders approve board nominees - Investing.com Australia
Mizuho cuts Vigil Neuroscience stock rating to neutral By Investing.com - Investing.com Nigeria
Mizuho cuts Vigil Neuroscience stock rating to neutral - Investing.com Australia
Sanofi to spend $470M for Watertown biotech’s Alzheimer’s drug - The Business Journals
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline - Pharmafile
Vigil Neuroscience Inc Azioni (VIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vigil Neuroscience Inc Azioni (VIGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
1.47%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):